Kevin Rynearson, PhD profile page

Dr. Kevin Rynearson is a medicinal chemist, translational scientist, and drug developer with more than a decade of experience advancing small-molecule therapeutics for the prevention and treatment of Alzheimer’s disease. His work has focused on the design and optimization of gamma-secretase modulators. Rynearson has helped establish a new class of pyridazine-derived compounds that demonstrate strong in vivo activity, drug-like characteristics, and disease-modifying potential for Alzheimer’s disease.

As chief scientific officer at Acta Pharmaceuticals, Rynearson leads research and development for a clinical candidate that emerged from his research and is being evaluated in a first-in-human trial. As head of research at CogniSHIELD Global, he also advocates for and supports research across general brain health, having helped to develop a science-based supplement designed to protect against normal age-related cognitive decline.